ReviewClinical ophthalmology (Auckland, N.Z.)2020
Treatment-Resistant Bacterial Keratitis: Challenges and Solutions.
Review in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Corneal cross-linking for infectious keratitis of various causes: an umbrella review.BMC ophthalmology · 2025Pooled it
- An eye drop combination for treating Staphylococcus aureus-induced keratitis in rats: repurposing ibuprofen.Scientific reports · 2026Article
- Sustained Ocular Delivery of Moxifloxacin-Ufasomes-Laden In Situ Gel for Keratitis Management.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Trends of Microorganisms and Antibiotic Resistance Isolated from Patients with Bacterial Keratitis from a Tertiary Hospital in Southeastern Korea: A 26-Year Retrospective Medical Record Review.Antibiotics (Basel, Switzerland) · 2026Article
- Antibiofilm and Immunomodulatory Effects of Cinnamaldehyde in Corneal Epithelial Infection Models: Ocular Treatments Approach.Pharmaceutics · 2025Article
- Microbial keratitis in the age of resistance: unlocking the therapeutic potential of phage therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Keratitis after keratoplasty: risk modifiers, microbial resistance and outcomes in the COVID-19 era.International ophthalmology · 2025Article
- Clinical characteristics and antibiotic susceptibility patterns of bacterial keratitis in the South of Vietnam.International ophthalmology · 2025Article
- Clinical Applications of Artificial Intelligence in Corneal Diseases.Vision (Basel, Switzerland) · 2025Review
- Zwitterionic chitosan-modified amorphous ZnCuAl-LDH eye drops for efficient treatment of bacterial keratitis.Materials today. Bio · 2025Article
- Wearing bacteriophages individually with an adhesive drug-loadable nanohelmet for treating ocular infections.Science advances · 2025Article
- Shifting trends in bacterial keratitis in a referral center.International ophthalmology · 2025Article
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- Distinct Ocular Surface Microbiome in Keratoconus Patients Correlate With Local Immune Dysregulation.Investigative ophthalmology & visual science · 2025Article
- Contact Lens-AssociatedClinical optometry · 2025Article
- A Multifunctional Cobalt-Containing Implant for Treating Biofilm Infections and Promoting Osteointegration in Infected Bone Defects Through Macrophage-Mediated Immunomodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Comparison of Collagen Cross-Linking Alone to 1% Povidone-Iodine Treatment of Refractory Corneal Ulcers: A Randomized Clinical Trial.Journal of ophthalmology · 2025Article
- Evaluation ofCurrent drug delivery · 2025Article
- Risk Factors, Clinical Characteristics, and Antibiotic Susceptibility Patterns ofAntibiotics (Basel, Switzerland) · 2024Article
- Microbial keratitis in the subtropical region of Korea: a comprehensive 12-year retrospective review at a single referral center.BMJ open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial keratitis is an important ophthalmic emergency and one of the most common causes of corneal blindness. The main causes of treatment resistance in bacterial keratitis are failure to eliminate predisposing factors, misdiagnosis and mistreatment. At first, exogenous, local and systemic predisposing factors that disturbing ocular surface must be eliminated to improve corneal ulcers and to prevent recurrences. Smears and scrapings for staining and culture are indispensable diagnostic tools for cases of sight-threatening keratitis (centrally located, multifocal, characterized by melting, painful). Main treatment agents in bacterial keratitis treatment are topical antibiotics. Until the results of culture antibiograms reach the ophthalmologist, empirical antibiotic selections based on direct microscopic examination and gram stain findings are the most appropriate initial treatment approach currently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.